Royalty Pharma (RPRX) CFO-linked entities execute planned share sales
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares in open-market transactions on April 1, 2026, at a weighted average price of $48.3318 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, indicating they were scheduled and not opportunistic. Despite these sales, Coyne and affiliated entities retain substantial holdings, suggesting a routine portfolio adjustment rather than a complete exit.
Royalty Pharma (RPRX) director granted 815-share equity award
Royalty Pharma plc director Bonnie L. Bassler was granted 815 Class A Ordinary Shares as an equity award, replacing a $37,500 quarterly retainer payment. The shares were issued at a reference price of $45.977 per share under the company’s 2020 Independent Director Equity Incentive Plan. Following this transaction, Bassler directly holds 73,947 Class A Ordinary Shares.
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma
Pablo Legorreta, founder and CEO of Royalty Pharma, revolutionized pharmaceutical funding by creating a model to purchase royalty streams on approved or late-stage drugs. This innovative approach provides immediate, non-dilutive capital to drug developers, accelerating medical innovation and generating significant returns for investors. Under his leadership, Royalty Pharma has become the world's largest buyer of pharmaceutical royalties, deploying over $25 billion and expanding across the entire drug development ecosystem.
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares worth approximately $1.58 million on March 23, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold at a weighted average price of $45.5287, near Royalty Pharma's 52-week high, with InvestingPro analysis suggesting the stock is overvalued. This transaction follows other strategic moves by Royalty Pharma, including a financing agreement with Zymeworks Inc. and key appointments to bolster AI capabilities and global reach.
Royalty Pharma EVP Coyne sells shares worth $1.58 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares for approximately $1.58 million. The sales were conducted under a pre-arranged 10b5-1 trading plan with shares trading near their 52-week high, although InvestingPro analysis suggests the stock is currently overvalued. Following these transactions, Coyne retains significant indirect and direct holdings in the company.
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan
Entities associated with Terrance P. Coyne, EVP & CFO of Royalty Pharma (RPRX), sold a total of 34,791 Class A Ordinary Shares on March 23, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in open-market transactions at a weighted average price of $45.5287 per share. Following these sales, the affiliated LLCs still hold significant shares in the company, and Coyne retains additional direct and indirect holdings.
RPRX SEC Filings - Royalty Pharma Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Royalty Pharma Plc (RPRX) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading reports. It details how the company, which acquires and manages royalty interests on biopharmaceutical products, discloses its financial and operational information. The platform also offers AI-powered summaries of complex sections and highlights recent insider transactions and corporate events.
RPRX SEC Filings - Royalty Pharma Plc 10-K, 10-Q, 8-K Forms
This page provides access to Royalty Pharma Plc (RPRX) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's royalty-based business model, capital structure, and portfolio performance, offering AI-powered summaries of complex sections. The article also highlights recent insider transactions, debt offerings, and financial results.
Royalty Pharma (RPRX) CFO linked entities sell 34,791 shares under 10b5-1 plan
Royalty Pharma's EVP and CFO, Terrance P. Coyne, reported indirect sales of 34,791 Class A ordinary shares on March 2, 2026. These transactions, executed through entities TPC RP 2021, LLC and TPC RP EPA1 LLC, were part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The shares were sold at weighted average prices between $46.67 and $47.01.
CFO-linked entities at Royalty Pharma (RPRX) sell 34,791 Class A shares
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold a total of 34,791 Class A Ordinary Shares in open-market transactions on February 23, 2026. These sales, executed at a weighted average price of $45.3165 per share, were conducted under a pre-established Rule 10b5-1 trading plan adopted in August 2025. The transactions were reported in a Form 4 SEC filing, indicating a negative sentiment for the filing's impact.
Trust-linked investor updates 5.7% Royalty Pharma (RPRX) Class A stake
R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini have updated their Schedule 13D filing for Royalty Pharma plc (RPRX), reporting a combined beneficial ownership of 24,223,082 Class A shares, representing 5.7% of the outstanding Class A shares as of February 19, 2026. The filing details holdings through MGG Strategic and GG Strategic sub-funds and notes adjustments to credit facility agreements which reduced the pledged Class A shares as collateral. Although the reporting persons and various linked entities are identified, they disclaim beneficial ownership for purposes of Section 13(d) of the Securities Exchange Act.
Royalty Pharma Earnings: Resounding Receipt Growth Caps Off Landmark Year
Royalty Pharma reported strong fourth-quarter results, with portfolio receipts reaching $874 million, marking an 18% year-over-year revenue increase. The company also announced four new royalty transactions valued at up to $4.7 billion and provided fiscal 2026 guidance, projecting a 5.5% receipt growth midpoint. This performance caps off what the company described as a landmark year.
Royalty Pharma Reports Q4 and Full Year 2025 Results
Royalty Pharma (RPRX) reported strong financial performance for Q4 and full year 2025, with significant increases in Portfolio Receipts, Adjusted EBITDA, and Portfolio Cash Flow. The company deployed $2.6 billion in royalty transactions and repurchased $1.2 billion in shares, while also raising its quarterly dividend. For 2026, Royalty Pharma projects continued growth in Portfolio Receipts and anticipates pivotal study results to drive additional value.
Royalty Pharma plc SEC 10-K Report
Royalty Pharma plc has released its 2025 10-K report, detailing a year of strategic acquisitions, strong financial performance, and operational achievements, including a 5.1% increase in total income and other revenues to $2,378.2 million. The company deployed $2.6 billion in new royalties and made strategic investments, while also repurchasing 37.4 million shares. The report also outlines challenges such as market and operational risks, regulatory changes, and market fluctuations that could impact future performance.
Royalty Pharma (Nasdaq: RPRX) posts double-digit 2025 growth and issues 2026 Portfolio Receipts guidance
Royalty Pharma (NASDAQ: RPRX) announced strong financial results for 2025, with Portfolio Receipts increasing by 16% to $3,254 million and Adjusted EBITDA rising by 16% to $2,966 million. The company also provided 2026 guidance, expecting Portfolio Receipts between $3,275 million and $3,425 million, representing a 3% to 8% growth in Royalty Receipts. This performance was driven by key products and significant capital deployment into royalty transactions, alongside substantial shareholder returns through share repurchases and dividends.
Drug-royalty giant Royalty Pharma spent $2.6B and bought back 37M shares
Royalty Pharma (RPRX) reported strong financial results for Q4 and full-year 2025, with Portfolio Receipts up 18% and 16% respectively. The company deployed $2.6 billion into royalty transactions, repurchased 37 million Class A shares for $1.2 billion, and increased its quarterly dividend by 7%. Royalty Pharma also provided positive guidance for full-year 2026 Portfolio Receipts, ranging from $3,275 million to $3,425 million.
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma plc announced it will release its Q4 and full-year 2025 financial results on February 11, 2026, before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. The company, a major buyer of biopharmaceutical royalties, provides details on its website and will archive the call for 30 days. This announcement includes an AI summary, potential positives and negatives, FAQs, insider trading data, revenue figures, hedge fund activity, and analyst ratings for RPRX stock.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 237,531 shares of Class A Ordinary Shares between February 2nd and February 4th, 2026, totaling over $10.3 million. These transactions were executed under a 10b5-1 plan and occurred in multiple tranches at varying prices. The article also notes recent company activities including a record funding market year, a dividend increase, and an acquisition.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold over $10.3 million in Class A Ordinary Shares between February 2nd and February 4th, 2026, through multiple transactions ranging from $42.0839 to $43.2928 per share. These sales were executed under a 10b5-1 plan adopted in August 2025. The company also reported a record year for the royalty funding market in 2025, increased its quarterly dividend, and completed a significant acquisition of the Evrysdi royalty.
Royalty Pharma EVP Coyne sells $10.3 million in shares
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold over $10.3 million worth of Class A Ordinary Shares between February 2nd and February 4th, 2026. These transactions were executed under a pre-arranged 10b5-1 plan. The article also notes recent company achievements, including a record year for the royalty funding market and an increase in its quarterly dividend.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold 237,531 Class A Ordinary Shares for over $10.3 million between February 2nd and February 4th, 2026. These transactions were executed via a 10b5-1 plan and represent a significant divestiture. The company recently reported a record year for royalty funding, a dividend increase, and completed a major acquisition, leading to an analyst upgrade from UBS.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. Despite the sale, Royalty Pharma recently announced a record year in royalty funding, increased its quarterly dividend, and made a significant acquisition of royalty rights for the spinal muscular atrophy treatment, Evrysdi.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $821,810 on January 30, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a record year in royalty funding, increased its quarterly dividend, and acquired the remaining royalty on the spinal muscular atrophy treatment, Evrysdi, for $240 million upfront.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, Executive Vice President, Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This sale was conducted under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma had a record year in royalty funding in 2025, increased its quarterly dividend, and acquired PTC Therapeutics' remaining royalty on Evrysdi for $240 million upfront, prompting UBS to upgrade the stock to Buy.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Marshall Urist, EVP at Royalty Pharma (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was part of a pre-arranged trading plan. Royalty Pharma also reported a record year in royalty funding, increased its quarterly dividend, and made strategic acquisitions including a royalty on PTC Therapeutics' Evrysdi.
Royalty Pharma stock hits 52-week high at $41.71
Royalty Pharma (RPRX) stock has reached a new 52-week high of $41.71, reflecting a 31.63% appreciation over the past year. The company boasts a $24 billion market capitalization, a 2.3% dividend yield, and has consistently raised its dividend for six consecutive years. Recent strategic moves include increased market share in royalty funding, a dividend raise, and the acquisition of the remaining royalty on Evrysdi, leading UBS to upgrade the stock to "Buy."
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan. The article also highlights Royalty Pharma's strong performance in 2025, including a record $10 billion in the royalty funding market and significant acquisitions.
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares worth approximately $2.7 million on January 20, 2026. The sales were made under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma reported a record year for the royalty funding market in 2025 and increased its quarterly dividend.
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026, through a pre-arranged trading plan. This transaction further details his remaining indirect and direct holdings in the company. In other news, Royalty Pharma maintained leadership in the royalty funding market in 2025, increased its quarterly dividend, and expanded its royalty interests with significant acquisitions of rights to Evrysdi and two cancer therapies.
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma plc announced it will release its fourth quarter and full year 2025 financial results on February 11, 2026, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. Eastern Time, with a replay available for 30 days. The company, founded in 1996, is a major buyer of biopharmaceutical royalties and funds innovation across the industry, holding royalties for over 35 commercial products and 20 development-stage candidates.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, Executive Vice President at Royalty Pharma, sold 20,000 Class A Ordinary Shares for approximately $815,634 on January 9, 2026, under a pre-arranged trading plan. Despite this insider selling, the company has shown aggressive share buybacks, boasts a "GREAT" financial health rating according to InvestingPro, and has raised its dividend for six consecutive years. Royalty Pharma recently reported a record year for the royalty funding market in 2025 and strategically acquired royalty interests in Roche’s Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com
Marshall Urist, EVP at Royalty Pharma, sold 20,000 Class A Ordinary Shares worth approximately $815,634 on January 9, 2026, though the company has been aggressively buying back shares. Royalty Pharma, with a $23.3 billion market cap, has raised its dividend for six consecutive years and maintained a significant market share in the royalty funding market in 2025. The company also recently made strategic acquisitions of royalty interests in Roche’s Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, Executive Vice President at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $815,634 on January 9, 2026, under a pre-arranged trading plan. Despite this insider selling, the company has been aggressively buying back shares and has raised its dividend for six consecutive years. Royalty Pharma reported a record year for the royalty funding market in 2025, deploying $2.6 billion in capital, and strategically acquired royalty interests in Roche's Evrysdi and two cancer therapies.
Urist Marshall, evp at Royalty Pharma, sells $815k in shares
Urist Marshall, EVP at Royalty Pharma (NASDAQ: RPRX), sold 20,000 Class A Ordinary Shares for approximately $815,634 on January 9, 2026, executed under a pre-arranged trading plan. Despite this insider sale, the company has been aggressively buying back shares. Royalty Pharma recently announced a record year for the royalty funding market in 2025, increased its dividend, and made strategic acquisitions, including 100% ownership of the royalty interest in Roche’s Evrysdi.
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing
An insider at Royalty Pharma plc (NASDAQ: RPRX) recently sold shares valued at $815,634, as disclosed in a new SEC filing. This transaction is part of the ongoing insider activity observed within the biopharmaceutical royalties company. The article also provides a summary of recent news for Royalty Pharma, including dividend declarations and new royalty acquisition agreements.
Royalty Pharma and Teva Pharmaceuticals Announce Up to $500 Million Funding Agreement for TEV-‘408 Development
Royalty Pharma and Teva Pharmaceuticals have entered an agreement where Royalty Pharma will provide up to $500 million to fund the development of Teva's anti-IL-15 antibody, TEV-‘408. This funding aims to accelerate the clinical trials for TEV-‘408, which is being investigated for vitiligo and celiac disease, starting with $75 million for a Phase 2b study in 2026. The collaboration highlights Teva's commitment to addressing unmet medical needs in autoimmune diseases and its "Pivot to Growth" strategy.
Assessing Royalty Pharma (RPRX) Valuation After Dividend Increase And Raised Full Year Guidance
Royalty Pharma (RPRX) has increased its quarterly dividend by 6.8% to US$0.235 per Class A share and raised its full-year guidance, leading to renewed attention on its valuation. While the current share price of US$40.17 is considered undervalued by some narratives, with a fair value around US$45.98, its P/E ratio of 22.4x is higher than the US pharmaceuticals average, suggesting a potential valuation risk. The company's future hinges on its cash flow management, deal pipeline, and operational efficiencies.
Royalty Pharma gives shareholders a 6.8% raise in quarterly payouts
Royalty Pharma (Nasdaq: RPRX) has announced a 6.8% increase in its quarterly dividend, raising it to $0.235 per Class A ordinary share for the first quarter of 2026. The dividend is scheduled for payment on March 10, 2026, to shareholders of record as of February 20, 2026. This move reflects the company's continuous funding of innovation in the biopharmaceutical industry.
Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20.
Royalty Pharma plc has declared an increase in its quarterly dividend for the first quarter of 2026, raising it to $0.235 per share from the previous $0.22. The dividend will be payable on March 10, 2026, to shareholders of record as of February 20, 2026. This announcement highlights the company's commitment to returning value to its shareholders.
Royalty Pharma increases quarterly dividend by 6.8% to $0.235
Royalty Pharma (NASDAQ:RPRX) has announced a 6.8% increase in its quarterly dividend to $0.235 per Class A ordinary share, marking its sixth consecutive year of dividend raises. The dividend is set to be paid on March 10, 2026, to shareholders of record as of February 20, 2026. This decision follows recent strategic acquisitions by the company, including royalty interests in Roche's Evrysdi and new cancer therapies, alongside a positive outlook from TD Cowen.
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase
Royalty Pharma plc announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase from the previous quarter. The dividend is scheduled for payment on March 10, 2026, to shareholders of record by February 20, 2026. This increase reflects the company's financial strength and its strategic position as a major buyer of biopharmaceutical royalties, supporting innovation across the industry.
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase
Royalty Pharma plc announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase from the prior quarter. The dividend is scheduled for payment on March 10, 2026, to shareholders of record as of February 20, 2026. This move highlights the company's financial strength and its role as a major buyer of biopharmaceutical royalties, funding innovation across the industry with a portfolio spanning over 35 commercial products.
Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend for the first quarter of 2026, raising it to $0.235 per Class A ordinary share. The dividend will be paid on March 10, 2026, to shareholders recorded by February 20, 2026. This reflects the company's continued financial performance and its role as a major funder of biopharmaceutical innovation.
Los Angeles Daily News - Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend, setting it at $0.235 per Class A ordinary share for the first quarter of 2026. This dividend will be paid on March 10, 2026, to shareholders of record as of February 20, 2026. The company, founded in 1996, specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
Royalty Pharma Announces Dividend Increase
Royalty Pharma plc announced a 6.8% increase in its quarterly dividend for the first quarter of 2026, setting it at $0.235 per Class A ordinary share. The dividend will be paid on March 10, 2026, to shareholders of record as of February 20, 2026. Royalty Pharma is a major buyer of biopharmaceutical royalties and funds innovation across the industry, holding royalties on over 35 commercial products and 19 development-stage candidates.
What's Going On With Royalty Pharma Stock Wednesday?
Royalty Pharma's stock has gained 53% year-to-date. This article details Royalty Pharma's recent acquisition of PTC Therapeutics' royalty on Roche's Evrysdi for up to $300 million and their previous acquisition of a royalty interest in Nuvalent Inc.'s neladalkib and zidesamtinib for up to $315 million. It also outlines the competitive landscape for spinal muscular atrophy treatments and the sales projections for the acquired drug royalties.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma has acquired a pre-existing royalty interest in Nuvalent’s oncology drugs, neladalkib and zidesamtinib, for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for NSCLC, with neladalkib showing positive pivotal results and zidesamtinib currently under FDA review. Analysts project significant sales for both therapies by 2035, securing Royalty Pharma a low-single-digit royalty on worldwide net sales until approximately 2041-2042.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma plc announced the acquisition of a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million. These next-generation tyrosine kinase inhibitors are in development for ALK and ROS1 mutation-positive non-small cell lung cancer, respectively. The transaction covers a low-single digit royalty on worldwide net sales for both therapies, with an expected duration extending through approximately 2041 to 2042.
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma has acquired a royalty interest in Nuvalent's next-generation therapies, neladalkib and zidesamtinib, for up to $315 million. These drugs target different forms of non-small cell lung cancer and have shown promising clinical results, with analysts projecting significant sales by 2035. The acquisition is expected to provide Royalty Pharma with low-single digit royalties on worldwide net sales, extending through approximately 2041-2042.
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Advances in novel therapies are accelerating survival gains for pancreatic cancer patients. Oncolytics Biotech Inc. is preparing for a pivotal Phase 3 study of pelareorep, an immunotherapy, in first-line metastatic pancreatic cancer, while Immuneering Corporation and Tango Therapeutics, Inc. have reported promising clinical data for their respective treatments. Moderna and Royalty Pharma plc are also investing in and supporting oncology advancements.
